A Phase 1A/1B, Open-Label, Multiple-Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Preliminary Antitumor Activities of the B RAF Inhibitor BGB 283 in Subjects With Solid Tumors.
Latest Information Update: 25 Oct 2024
At a glance
- Drugs Lifirafenib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors BeiGene
- 17 Mar 2020 Results published in the Journal of Clinical Oncology
- 22 Jul 2018 Status changed from active, no longer recruiting to completed.
- 02 Apr 2017 Results published in a BeiGene Media Release.